Capricor Therapeutics

CAPR

Market cap $291M

Shares of Capricor Therapeutics, Inc. (NASDAQ: CAPR) plummeted Monday due to a short call from controversial former pharmaceutical executive Martin Shkreli.

Capricor Therapeutics, Inc. ( CAPR ) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Anthony Bergmann - CFO & Corporate Treasurer Linda Marbán - Co-Founder, President, CEO & Director Conference Call Participants Edward Tenthoff - Piper Sandler & Co., Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Joseph Pantginis - H.C. Wainwright & Co, LLC, Research Division Kristen Kluska - Cantor Fitzgerald & Co., Research Division Catherine Novack - JonesTrading Institutional Services, LLC, Research Division Madison Wynne El-Saadi - B.

NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) breached their fiduciary duties to shareholders.

–Publication highlights Deramiocel's anti-fibrotic activity and describes a validated potency assay supporting quality control and product consistency in late-stage development–

Company to Host Conference Call on November 10, 2025, at 4:30 p.m. ET Company to Host Conference Call on November 10, 2025, at 4:30 p.m. ET

Capricor (CAPR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

NEW YORK , Oct. 28, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Capricor Therapeutics, Inc. (NASDAQ: CAPR)  breached their fiduciary duties to shareholders.  According to a federal securities lawsuit, Insiders at Capricor Therapeutics provided investors with material information concerning Capricor's lead cell therapy candidate drug deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy.

Capricor allegedly misled investors about its DMD therapy's FDA approval prospects; an FDA rejection letter citing lack of efficacy data sent shares down.

SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential legal claims on behalf of Capricor Therapeutics, Inc. (NASDAQ: CAPR) shareholders, concerning alleged misconduct by certain officers and directors that may have harmed the company and its investors.

Capricor Therapeutics is advancing deramiocel (CAP-1002) for DMD cardiomyopathy, with a BLA resubmission and HOPE-3 topline data expected by 2026. CAPR's therapy addresses a critical unmet need in non-ambulatory DMD patients, offering a unique mechanism and favorable safety profile compared to gene therapies like Elevidys. Strong regulatory designations, strategic partnerships, and a robust cash position support ongoing R&D, despite elevated burn and recent FDA setbacks.